썸네일
2023
- 04
- Selected as a Super-gap Technology Startup 1000+ (DIPS 1000+) Project from the Ministry of SMEs and Startups
썸네일
2022
- 09
- Selected as a non-clinical development project from National New Drug Development Program by KDDF (Korea Drug Development Fund)
- 06
- Signed MOU with K-MEDI hub for Research Collaboration Agreement
Signed licensing agreement with K-MEDI hub / MFC0101 Licensing-in
A MEDICHEM team is formed
- 04
- Received Series A Institutional Funding
- 04
- Joint research contract for the development of cancer immunotherapy (Seoul National University College of Medicine) / MFC0101
Joint CSO contract with ShiftBio for the development of exosome-based cancer immunotherapy
- 03
- Signed intellectual property consulting agreement contract with United One Law Group LLC.
- 02
- Joint research contract with Korea University for the discovery of cancer stem cell-based therapy
썸네일
2021
- 12
- Headquarter/Research center relocated to 7F WOOJUNGBIO Cluster, 593-8 Dongtangiheung-ro, Hwaseong-si, Gyeonggi-do, 18469, Republic of Korea
- 08
- Joint research contract for the development of Anti-viral treatment (Chungbuk National University College of Medicine) / MFC0102
- 03
- Joint research contract with Korea University for the development of NASH treatment / MFC0102
썸네일
2020
- 09
- Joint research contract with Korea University for the discovery of cancer stem cell-based therapy
- 08
- Joint research contract for the development of Anti-viral treatment (Chungbuk National University College of Medicine) / MFC0102
- 07
- Joint research contract with K-MEDI hub for the development of 'First-in-Class drug' (Structural Biology) / MFC0301
- 04
- Appointed as military service designated company from Military Manpower Administration
- 03
- Joint research contract with K-MEDI hub for the development of 'First-in-Class drug' (Molecular design) / MFC0301
썸네일
2019
- 09
- Joint research contract with K-MEDI hub for the development of 'First-in-Class drug' (Structural Biology) / MFC0101
Joint research contract with K-MEDI hub for the development of 'First-in-Class drug' (Lead Optimization) / MFC0101
- 08
- Joint research contract with Korea University for the discovery of cancer stem cell-based therapy
- 07
- Granted One-Stop support project with K-MEDI hub
- 06
- Received Pre-Series A Institutional Funding
- 02
- Certified as venture company from KOITA (#20190100921)
썸네일
2018
- 07
- Certified as Research Institute in MEDIFIC
- 02
- Founded at Korea University, Seoul, South Korea